Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 973-982

  Zhang, Nian Hua ^a,b   Li, Jie ^c   Li, Yin ^c   Zhang, Xin Tao ^d   Liao, Wen Ting ^a   Zhang, Jun Yi ^a   Li, Rong ^a   Luo, Rong Cheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

CD133; Colon cancer; CXCR4; Immunohistochemistry

Indexed keywords

CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

EID: 84859463434     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.527     Document Type: Article

References (50)

1. Weir HK, Thun MJ, Hankey BF, et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: 1276-1299, 2003.
2. Singh R, Lillard JW Jr and Singh S: Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed) 3: 1569-1582, 2011.
3. Liekens S, Schols D and Hatse S: CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16: 3903-3920, 2010.
4. Arya M, Patel HR and Williamson M: Chemokines: key players in cancer. Curr Med Res Opin 19: 557-564, 2003.
5. Ali S and Lazennec G: Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26: 401-420, 2007.
6. Murdoch C: CXCR4: chemokine receptor extraordinaire. Immunol Rev 177: 175-184, 2000.
7. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP and Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676-1686, 2003.
8. Kawamata H, Furihata T, Omotehara F, et al: Identification of genes differentially expressed in a newly isolated human metastasizing esophageal cancer cell line, T. Tn-AT1, by cDNA microarray. Cancer Sci 94: 699-706, 2003.
9. Bachelder RE, Wendt MA and Mercurio AM: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62: 7203-7206, 2002.
10. Kijima T, Maulik G, Ma PC, et al: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62: 6304-6311, 2002.
11. Gao Z, Wang X, Wu K, Zhao Y and Hu G: Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 10: 186-193, 2010.
12. Guleng B, Tateishi K, Ohta M, et al: Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65: 5864-5871, 2005.
13. Koshiba T, Hosotani R, Miyamoto Y, et al: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6: 3530-3535, 2000.
14. Van der Meulen AA, Biber K, Lukovac S, et al: The role of CXC chemokine ligand (CXCL)12-CXC chemokine receptor (CXCR)4 signalling in the migration of neural stem cells towards a brain tumour. Neuropathol Appl Neurobiol 35: 579-591, 2009.
15. Li W, Gomez E and Zhang Z: Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res 26: 527-533, 2007.
16. Chen GS, Yu HS, Lan CC, et al: CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol 154: 910-918, 2006.
17. Barbero S, Bonavia R, Bajetto A, et al: Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 63: 1969-1974, 2003.
18. Zeelenberg IS, Ruuls-Van Stalle L and Roos E: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63: 3833-3839, 2003.
19. Kato M, Kitayama J, Kazama S and Nagawa H: Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5: 144-150, 2003.
20. Uchida D, Begum NM, Almofti A, et al: Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 290: 289-302, 2003.
21. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
22. Todaro M, Francipane MG, Medema JP and Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162, 2010.
23. Boman BM and Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol 26: 2795-2799, 2008.
24. Wang J, Guo LP, Chen LZ, Zeng YX and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724, 2007.
25. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27: 844-850, 2009.
26. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
27. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
28. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
29. Hambardzumyan D, Squatrito M and Holland EC: Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10: 454-456, 2006.
30. Clement V, Sanchez P, de Tribolet N, Radovanovic I and Ruizi Altaba A: HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17: 165-172, 2007.
31. Hambardzumyan D, Becher OJ and Holland EC: Cancer stem cells and survival pathways. Cell Cycle 7: 1371-1378, 2008.
32. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
33. Griguer CE, Oliva CR, Gobin E, et al: CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3: e3655, 2008.
34. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
35. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007.
36. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
37. Monzani E, Facchetti F, Galmozzi E, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946, 2007.
38. +cells with cancer stem cell characteristics. Breast Cancer Res 10: R10, 2008.
39. Boman BM and Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26: 2828-2838, 2008.
40. Matsumoto K, Shariat SF, Ayala GE, Rauen KA and Lerner SP: Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 66: 441-446, 2005.
41. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749, 2005.
42. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A and Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122: 91-99, 2008.
43. Schrader AJ, Lechner O, Templin M, et al: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86: 1250-1256, 2002.
44. Sasaki K, Natsugoe S, Ishigami S, et al: Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer. J Surg Oncol 97: 433-438, 2008.
45. Kim J, Takeuchi H, Lam ST, et al: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23: 2744-2753, 2005.
46. Schimanski CC, Schwald S, Simiantonaki N, et al: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11: 1743-1750, 2005.
47. Ottaiano A, Franco R, Aiello Talamanca A, et al: Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 12: 2795-2803, 2006.
48. Todaro M, Alea MP, Di Stefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402, 2007.
49. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
50. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 99: 1578-1583, 2008.